Import Disodium Clodronate Tetrahydrate — Buy in Bulk from Supplier in China

Disodium clodronate tetrahydrate is a bisphosphonate compound with the molecular formula CH2Cl2Na2O6P2·4H2O and CAS number 88416-50-6. It is a white to off-white crystalline powder with a molecular weight of 360.92 g/mol, used primarily in pharmaceutical formulations for treating metabolic bone diseases. The compound inhibits osteoclast-mediated bone resorption and is a key ingredient in drugs for osteoporosis, Paget’s disease, and hypercalcemia of malignancy.

The product is manufactured to pharmaceutical-grade standards, with high purity and controlled crystalline structure. While the supplier claims high solubility and stability, no specific assay, purity percentage, or residual solvent limits are provided. The tetrahydrate form is preferred in formulations for its predictable hydration behavior. Typical impurities to monitor include free chloride, phosphorus-containing by-products, and water content variation. No certification claims such as ISO or SGS are substantiated in the listing.

This compound is used by pharmaceutical manufacturers, research institutions, and compounding pharmacies for injectable and oral formulations. Buyers include generic drug producers in Europe, North America, and Asia seeking bulk active pharmaceutical ingredients. Packaging is not specified, but standard practice is 1 kg or 5 kg HDPE drums with desiccant. Trade terms such as MOQ, lead time, and Incoterms are not stated. Buyers must request these details directly, and confirm compliance with pharmacopeial standards like USP, EP, or JP.

Jinlan Pharm-Drugs Technology Co., Ltd. is a company based in Hangzhou, China, with a registered address at Modern Star, Shaoxing Road. The supplier is classified as imported-tier and harbor-tier, indicating minimal platform verification. No documentation is provided regarding GMP certification, facility audits, or years of operation. The listing does not mention production scale, laboratory facilities, or quality control procedures beyond vague references to international standards.

There is no evidence of regulatory submissions, pharmacopeial compliance, or client references. The supplier claims compliance with ISO and SGS, but no certificates or audit reports are attached or referenced. Response rate and average response time are zero, suggesting limited buyer support capacity. Buyers must treat this as a raw material supplier without public quality assurance infrastructure. Direct verification of manufacturing controls and batch traceability is essential before procurement.